RUXOPEG is the first study to formally assess the safety and efficacy of Rux + IFNa combination in MF patients never exposed to either drugs before First in ASH 2018 Series by David Wallace Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. […]
Breaking news on Celgene’s Fedratinib for Myelofibrosis patients!
by David Wallace Fedratinib by Celgene, offered on Expanded Access Program (EAP) for Myelofibrosis Patients This is hot off the press! So hot, that no one has covered it until now – brought to you by PV Reporter. I knew after combing through the ASH (American Society of Hematology) abstracts that something was missing. That […]
Safety and efficacy of combo therapy of interferon-a2 and ruxolitinib in polycythemia vera and myelofibrosis
by Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Christen Bertel Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Vibe Skov, Hans Carl Hasselbalch Abstract Interferon‐α2 reduces elevated blood cell counts […]
03: Learn Benefits of Becoming your own MPN Patient Advocate
MPN Chronicles Podcast – 03, PV Reporter, Day 3, 2nd Trip to ER in 3 Days by David Wallace Chest pain continued to worsen after 1st trip to the ER, 2 days earlier. This was an immediate cause for immediate concern and a return trip to the ER on day 3 with Polycythemia Vera (PV). […]
Spotlight on MPN Life
Publisher’s Note: PV Reporter will spotlight organizations and online MPN support groups from time to time that have a unique message to share and help MPN patients as well. I have known Jeremy since I first got involved in the Facebook Support Groups 9 years ago. He had a positive influence on me personally and […]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 42
- Next Page »
